Recent Trends in Hematology/ Oncology

Research shows that combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells shows activity for relapsed or refractory multiple myeloma. Explore more hemonc at: http://bit.ly/2xaW3zT